logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
Q2 2019
ASSEMBLY BIOSCIENCES, INC.
Interim results from phase IIa study of ABI-H0731 (ABI-H0731-202)
Hepatitis B virus (HBV)
Q2 2019
Axsome Therapeutics, Inc.
Topline results from phase II trial of AXS-12 (reboxetine) (CONCERT)
narcolepsy, a sleep disorder
Q2 2019
Novus Therapeutics, Inc.
Data from phase I Pharmacodynamic Effects Trial of OP0201
Otitis Media
Q2 2019
Novus Therapeutics, Inc.
Data from second cohort of phase I trial of OP0201
Otitis Media
Q2 2019
Constellation Pharmaceuticals, Inc.
Interim data update from phase II trial of CPI-0610 (MANIFEST)
Myelofibrosis
Q2 2019
Constellation Pharmaceuticals, Inc.
Data from phase Ib portion of phase Ib/II trial of CPI-1205 with either abiraterone or enzalutamide (ProSTAR)
Metastatic castration-resistant prostate cancer (mCRPC)
Q2 2019
Provention Bio, Inc.
Top-line data from phase 1b clinical trial of PRV-300 (PULSE)
Moderate-to-severe ulcerative colitis
Early Apr 2019
Dermira Inc.
Topline efficacy and safety results from dose-ranging study of Lebrikizumab
Moderate-to-severe atopic dermatitis
Q2 2019
Corvis Corp
Resubmission of NDA for Brinavess
Rapid conversion of recent onset atrial fibrillation
Q2 2019
Aerpio Pharmaceuticals, Inc.
Top-line data from phase II study of AKB-9778 (TIME-2b)
Non-proliferative diabetic retinopathy
Q2 2019
Arbutus Biopharma Corp.
Top line results from phase I trial of AB-506
Hepatitis B Virus (HBV)
Q2 2019
Myovant Sciences Ltd
Top-line data from 1st phase III trials of Relugolix (LIBERTY 1)
Heavy menstrual bleeding associated with uterine fibroids in Women
Q2 2019
CTI BioPharma Corp.
Full top-line data from ongoing phase II study of Pacritinib (PAC203)
Myelofibrosis
Q2 2019
Heat Biologics Inc.
Final data from Phase II readout of HS-110
Non Small Cell Lung Cancer (NSCLC)
Q2 2019
Heat Biologics Inc.
Interim data from ComPACT trial of HS-130
Non Small Cell Lung Cancer (NSCLC)
Q2 2019
Celsion Corp.
Data from 1st interim efficacy results from phase III study of ThermoDox (OPTIMA)
primary liver cancer
Early Mar 2019
Insys Therapeutics, Inc.
Results from nonclinical juvenile toxicity study related to naloxone
opioid overdose
28-Feb-2019
Heat Biologics Inc.
New interim data from ongoing phase II trial of HS-110 plus with Opdivo combination
Advanced non-small cell lung cancer (NSCLC)
20-Feb-2019
Gamida-Cell Ltd.
New data from ongoing phase I study of NAM-NK
Non-Hodgkin lymphoma and multiple myeloma
20-Feb-2019
Gamida-Cell Ltd.
Initial data from a Phase 1/2 study of NiCord
Severe aplastic anemia
15-Feb-2019
Bausch Health Companies Inc.
BHC, BHC.TO
Resubmission of NDA for DUOBRII Lotion
Topical treatment of plaque psoriasis
08-Feb-2019
Catalyst Biosciences Inc.
Data from ongoing Phase 2/3 trial of marzeptacog alfa (MarzAA)
Hemophilia A or B with inhibitors
07-Feb-2019
Protalix BioTherapeutics Inc.
Preliminary pharmacokinetic data from phase III study of Pegunigalsidase alfa (BRIGHT)
Fabry disease
07-Feb-2019
Sangamo Biosciences Inc
Data from Preliminary safety and biochemical changes at up to 4 weeks from Phase 1/2 clinical trial of SB-318
Mucopolysaccharidosis Type I or MPS I in adults
07-Feb-2019
Sangamo Biosciences Inc
Update on safety and biochemical changes at up to 24 weeks from Phase 1/2 clinical trial of SB-913 (CHAMPIONS)
Mucopolysaccharidosis Type II or MPS II in adults